No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group.
Behringer
K
K
German Hodgkin Study Group, First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany. Electronic address: karolin.behringer@uk-koeln.de.
Wildt
L
L
University Hospital for Gynecology and Reproduction Medicine.
Mueller
H
H
German Hodgkin Study Group, First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Mattle
V
V
University Hospital for Gynecology and Reproduction Medicine.
Ganitis
P
P
German Hodgkin Study Group, First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
van den Hoonaard
B
B
German Hodgkin Study Group, First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Ott
H W
HW
Institute of Medical and Chemical Laboratory Diagnostics (ZIMCL), University Hospital Innsbruck, Innsbruck, Austria.
Hofer
S
S
Institute of Medical and Chemical Laboratory Diagnostics (ZIMCL), University Hospital Innsbruck, Innsbruck, Austria.
Pluetschow
A
A
German Hodgkin Study Group, First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Diehl
V
V
German Hodgkin Study Group, First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Engert
A
A
German Hodgkin Study Group, First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Borchmann
P
P
German Hodgkin Study Group, First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
D000293:Adolescent; D000328:Adult; D054304:Anti-Mullerian Hormone / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D015331:Cohort Studies; D003276:Contraceptives, Oral / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005858:Germany; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D006080:Ovarian Follicle / Q000187:drug effects*; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
D003276:Contraceptives, Oral; D001761:Bleomycin; D007987:Gonadotropin-Releasing Hormone; D011344:Procarbazine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D054304:Anti-Mullerian Hormone; D003520:Cyclophosphamide; D011241:Prednisone